biostudies-literatureUnknown13Qin W<h4>Introduction</h4>Recent developments in immune checkpoint inhibitors (ICIs) have improved the treatment outcomes of esophageal cancer (EC); however, it may initiate immune-related adverse events (irAEs) in some patients. The ICIs' therapeutic efficacy is associated with irAEs in patients with non-small cell lung cancer or renal cell carcinoma, although this association is unknown in EC. The purpose of this study was to explore the association between irAEs and the efficacy of programmed death 1 (PD-1) inhibitors in EC patients.<h4>Patients and methods</h4>This study included patients with advanced EC treated with PD-1 inhibitors. The patients were divided into two groups according to the occurrence of irAEs. Afterward, the efficacy was compared between the irAE-negative and irAE-positiFrontiers in immunology931429https://www.ebi.ac.uk/biostudies/studies/S-EPMC9554876biostudies-literatureAssociation between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer.PMC9554876Yang LZou BQin WLi BFan BDuan YWang LfalseAssociation between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer.<h4>Introduction</h4>Recent developments in immune checkpoint inhibitors (ICIs) have improved the treatment outcomes of esophageal cancer (EC); however, it may initiate immune-related adverse events (irAEs) in some patients. The ICIs' therapeutic efficacy is associated with irAEs in patients with non-small cell lung cancer or renal cell carcinoma, although this association is unknown in EC. The purpose of this study was to explore the association between irAEs and the efficacy of programmed death 1 (PD-1) inhibitors in EC patients.<h4>Patients and methods</h4>This study included patients with advanced EC treated with PD-1 inhibitors. The patients were divided into two groups according to the occurrence of irAEs. Afterward, the efficacy was compared between the irAE-negative and irAE-positi2022-01-01T00:00:00Z20222025-04-18T22:55:26.298Z2025-04-07T10:41:27.224ZS-EPMC95548763624878210.3389/fimmu.2022.931429